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ABSTRACT
Among the emerging subunit vaccines are recombinant protein- and synthetic peptide-based vaccine
formulations. However, proteins and peptides have a low intrinsic immunogenicity. A common strategy to
overcome this is to co-deliver (an) antigen(s) with (an) immune modulator(s) by co-encapsulating them in
a particulate delivery system, such as poly(lactic-co-glycolic acid) (PLGA) particles. Particulate PLGA
formulations offer many advantages for antigen delivery as they are biocompatible and biodegradable;
can protect the antigens from degradation and clearance; allow for co-encapsulation of antigens and
immune modulators; can be targeted to antigen presenting cells; and their particulate nature can increase
uptake and cross-presentation by mimicking the size and shape of an invading pathogen. In this review
we discuss the pros and cons of using PLGA particulate formulations for subunit vaccine delivery and
provide an overview of formulation parameters that inﬂuence their adjuvanticity and the ensuing immune
response.
KEYWORDS
antigen; adjuvant; dendritic
cells; delivery systems;
microparticles; nanoparticles;
PLGA; subunit; vaccine
Introduction
Vaccination consists of the administration of antigens in
order to elicit an adaptive antigen-speciﬁc immune response
and confer long-term protection against subsequent expo-
sure to the antigen.1 Traditional vaccine formulations, con-
sisting of either live attenuated or killed pathogens, have
been very successful in the last century to drastically reduce
the incidence of widespread infectious diseases.2,3 Still,
despite their success,4,5 this traditional vaccine approach has
not resulted in effective vaccines against disease like AIDS,
tuberculosis, or cancer. These issues have led to the demand
for alternatives and vaccine development shifted from using
whole inactivated pathogens to subunits of the pathogen.
These subunits may be natural or recombinant antigenic
proteins, peptides, capsular polysaccharides or any speciﬁc
part of the pathogen which has been demonstrated to stim-
ulate a protective immune response. Examples of subunit
vaccines include hepatitis B, tetanus, diphtheria, pneumo-
coccus and human papillomavirus (HPV) vaccines. How-
ever, the need for eliciting both humoral and cellular
immune responses has limited the efﬁcacy of subunit vac-
cines. While subunits are safer than whole pathogens, they
generally are less immunogenic, demanding the use of adju-
vants.5 Adjuvants are immunostimulatory molecules and/or
delivery systems 6 used in vaccine formulations to enhance
the magnitude of antigen-speciﬁc immune responses.
Immunostimulatory molecules activate the immune sys-
tem through their interaction with speciﬁc receptors of
APCs, which recognize evolutionary conserved molecular
motifs associated with groups of pathogens, the pathogen-
associated molecular patterns (PAMPs). These membrane-
bound pattern recognition receptors (PRRs) include nucleo-
tide-binding oligomerization domain (NOD)-like receptors
(NLRs), C-type lectin receptors (CLRs) and Toll-like recep-
tors (TLRs). PAMPs have been shown to enhance and mod-
ulate the immune response when mixed, conjugated, or co-
delivered together with antigen.7,8 This knowledge opens
the door to the rational design of vaccine formulations that
co-deliver PAMPs to increase the immunogenicity of the
antigen.
Next to immunostimulatory molecules, subunit vaccines
may beneﬁt from encapsulation in particulate delivery systems,
which include microparticles (MP) (> 1 mm) and nanopar-
ticles (NP) (< 1000 nm). Particles may promote immunogenic-
ity through the following mechanisms:
1. Stability improvement of the antigen: particulate delivery
systems can protect encapsulated or associated antigen
from chemical and enzymatic degradation and rapid
clearance via the kidneys, resulting in increased residence
time 1,6
2. Controlled antigen release: particulate formulations can
be tailored to serve as extra- and/or intracellular depot
for sustained release of the antigen, increasing antigen
exposure to DCs and prolonged antigen presentation,
respectively 9
3. Facilitated DC uptake: particulate delivery systems can
mimic the size and shape of an invading pathogen, which
facilitates uptake by DCs 7,10
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4. Targeted delivery: particles per se are passively directed
to APCs because of their particulate form, but can also
be speciﬁcally targeted to speciﬁc tissues or subsets of
immune cells (like DCs) via targeting moieties, such as
TLR ligands or DC-speciﬁc antibodies 11-14
5. Enhanced cross-presentation: particles may facilitate
endosomal escape, which is a known mechanism leading
to antigen cross-presentation by DCs and induction of a
CTL response 15,16
6. Concomitant delivery of multiple components: partic-
ulate formulations can co-deliver a combination of
molecules, such as (multiple) antigens and/or immu-
nostimulatory molecules and/or targeting ligands,
mimicking pathogens and facilitating uptake by APCs
and stimulating immune activation 9,10
7. Regulation of the type of immune response: immunolog-
ical properties of particles can be tailored by changing
their size, surface charge, or hydrophobicity 1,6
Owing to the potential synergistic effect of all the above-
mentioned effects, particles can also serve to decrease the dose
of antigen required to elicit an immune response.7
A large number of particulate systems has been reported,
such as polymeric particles, liposomes, virus-like particles, viro-
somes, immunostimulating complexes (ISCOMs), emulsions,
and inorganic nanobeads. Among these, poly(D,L-lactide-co-
glycolide) (PLGA)-based delivery systems have been particu-
larly well studied and are promising candidates for antigen
delivery.17 Since the initial description of PLGA particle as
potential adjuvants by O’Hagan et al,18 PLGA particles have
been formulated in a wide variety of ways resulting in various
size, charge, antigen stability, loading capacity and release pro-
ﬁles. These key formulation aspects can greatly affect the
potency of the vaccine and will be discussed in detail in this
review.
PLGA particulate systems for subunit vaccine delivery
PLGA and its derivatives are aliphatic polyesters that are
available in different ratios of lactic acid and glycolic acid,
various molecular weights, and type of end groups (ester-ter-
minated (capped) or carboxylic acid terminated (uncapped)).
PLGA polymers have been widely studied over the past few
decades for several biomedical applications because of their
excellent safety records, varying from sutures to bone recon-
struction, as well as in implants and particles for sustained
drug delivery, and it has long been approved for parenteral
human use by the FDA.19-21 After their administration,
PLGA particles undergo degradation by bulk erosion, during
which water diffuses into the polymeric matrix, hydrolyzing
the ester bonds throughout the polymer and reducing its
molecular weight until degradation products are formed that
can be dissolved.6 This process increases porosity of the
matrix, allowing the sustained release of the entrapped mate-
rial as degradation continues. Finally, PLGA is hydrolyzed
into the original monomers, lactic acid and glycolic acid,
which are by-products of various metabolic pathways and
are not associated with signiﬁcant toxicity.22 The degradation
rate of PLGA is related to molecular weight, hydrophilicity
and crystallinity, but also other factors such as pH of the
medium, water uptake rate, process of ester hydrolysis, swell-
ing ratio and degradation by-products.6,23 Lower molecular
weight molecules degrade faster, as shorter molecules can be
more easily hydrolyzed and dissolved, leaving the polymeric
matrix. Higher hydrophilicity can also lead to faster degrada-
tion: the hydophilicity is mainly inﬂuenced by the mono-
mers’ ratio, with glycolic acid being more hydrophilic than
lactic acid, so the higher the content of glycolic acid, the
more hydrophilic, increasing hydrolysis rate.22 An exception
to this rule is the co-polymer with 50:50 lactide:glycolide
ratio, which has the fastest degradation rate, even among
polymer compositions with higher glycolic acid content.
This is due to the inﬂuence of crystallinity: the higher the
crystallinity, the slower the degradation, and at a 50:50 ratio
the polymer is the least crystalline, resulting in the fastest
degradation rate.6,24 Uptake of PLGA particles by APCs may
further expedite the degradation of PLGA, as the acidic envi-
ronment of the endosomal compartment (pH ~4.5 – 6.5)25
accelerates degradation compared to physiological pH (pH
7.4) since low pH catalyzes breakage of the ester linkage of
the polymer backbone.26,27 Thus, depending on the type of
PLGA polymer used, PLGA particles can be made with dis-
tinct release kinetics.12,28-30 Next to release characteristics
various other physical traits of PLGA particles can be manip-
ulated including particle size, size distribution, zeta potential,
polydispersity index, encapsulation efﬁciency and drug load-
ing.23 PLGA particles can be prepared by a variety of differ-
ent methods, most commonly used for protein and peptide
antigens being the double emulsion with solvent evaporation
method.22 Using this method, all previously mentioned char-
acteristics can be controlled during the assembly of the par-
ticles and can be produced according to good manufacturing
practice in a scalable, affordable and reproducible way.22 Sev-
eral analytical methods can be used to characterize the physi-
cochemical properties of particles and encapsulated
antigens.31,32 (see Table 1 for examples of commonly used
techniques).
While many properties are favorable and controllable, there
are also drawbacks in using PLGA particles as a delivery sys-
tem, especially concerning the stability of encapsulated protein
antigens, which will be discussed in more detail later on. There-
fore, antigen stability after encapsulation and storage should be
evaluated, and each formulation should be speciﬁcally custom-
ized for each antigen, accordingly to its properties.5 Still, con-
sidering that naked antigen has a very short residence time
because of rapid degradation and clearance upon administra-
tion,1,6 the drawbacks are neglectable compared to the advan-
tage of protection from the surrounding environment offered
by encapsulation.
1 PLGA particle characteristics affecting adjuvanticity
Depending on the preparation method and conditions, PLGA
particles can be made with diameters ranging from about
80 nm to 250 mm.8 Moreover, various experimental conditions
can be chosen and varied, such as type of solvent and polymer,
polymer molecular weight, polymer concentration, type and
concentration of surfactants, homogenization mechanism,
duration and intensity, or volume ratio of phases. Each of these
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different factors can affect the particle size, size distribution,
zeta potential, encapsulation efﬁciency, drug loading and
release proﬁle,23 which in turn affect the immunogenicity of
the formulation. In the following sections we will systemically
review these effects.
Particle size
Particle size of PLGA particles is one of the most critical factors
affecting their interaction with APCs as well as their biodistri-
bution. Particle size is strongly dependent on the preparation
process parameters, such as type and concentration of surfac-
tants, polymer concentration, phase volume ratios and homog-
enization speed.23 Higher polymer concentration leads to
bigger particles, due to higher viscosity of the oil phase, making
it harder to break the droplets. Higher inner water-in-oil emul-
sion (w1/o) to outer aqueous phase (w2) ratios [(w1/o)/w2]
also lead to larger particles, due to higher solidiﬁcation rate,
while higher surfactant concentrations lead to more stable
emulsions and can produce smaller particles.23 The method of
homogenization and its speed are also among the most impor-
tant factors: for instance, microparticles are usually produced
by using homogenizers and/or magnetic stirring, whereas
nanoparticles are produced by sonication, since the higher the
homogenization speed, the smaller the particles.
Particle size is known to inﬂuence the loading capacity,
depot formation and release kinetics.33-35 The particle size and
size distribution affect the antigen release rate, as the total sur-
face area for protein delivery depends on the particle size.23 On
the one hand, the smaller the particle, the faster the antigen
release, as smaller particles have a larger surface area, and
therefore a greater proportion of antigen located near their sur-
face, which can lead to a higher burst release.36,37 On the other
hand, microparticles have larger cores from which the encapsu-
lated antigen slowly diffuses out, and require more time to be
degraded, resulting in lower release rates.37
Smaller particles are generally regarded as more effective
delivery vehicles, since their size would allow easier travel
through epithelia and other biological barriers and efﬁciently
reach target tissues.38-40 The impact of antigen delivery system
size on the resultant immune response also depends on the
route of administration employed. Particles in the size range of
20-50 nm are suitable for transport through lymphatic vessels
to reach lymph nodes, where they can increase the probability
of immune cell interaction, but are not suitable for inhalable
vaccination.1,6 In contrast, large particles (500–2000 nm)
require cellular transport by APCs to be delivered to lymph
nodes.39 However, there is still no deﬁnitive answer to which
size PLGA particles are the most effective for vaccine delivery,
and results of different studies comparing nanoparticles and
microparticles are somewhat contradictory.29,34,35 A strong cor-
relation between particle size and the mechanism of antigen
uptake, processing and presentation by APCs has been reported
in different studies.33-35,41-43 APCs are known to take up and
process particles with dimensions comparable to viruses and
bacteria.44 The way APCs take up the vaccine can determine
how they process the antigen. Soluble antigens are preferen-
tially presented by the MHC class II pathway and are poorly
cross-presented. Particles in the range of 20-200 nm are efﬁ-
ciently taken up by DCs via endocytosis or pinocytosis and
facilitate the induction of cellular immune responses, whereas
microparticles of 0.5–5 mm are taken up via phagocytosis or
macropinocytosis, mainly generating humoral responses.34,35,45
Particles larger than 10 mm are hardly taken up, leading to
defective immune activation.46-48 It has also been postulated
that large microparticles (> 10 mm) preferentially attach to the
surface of macrophages, thus serving as an extracellular depot
system for continuous antigen release.35 Comparative studies
about the effect of PLGA particle size on the observed immune
response have been summarized in Table 2. These studies sug-
gest that the efﬁciency of internalization signiﬁcantly affects the
resulting immune response. However, one should bear in mind
that particle properties other than size may also affect their fate
and biological effects (see following sections).
The size of MPs should not be too large, as Thomas et al.
showed that hepatitis B surface antigen (HBsAg) in PLGA MPs
with a size of 5 mm elicited a signiﬁcantly higher serum anti-
body response than 12 mm MPs upon pulmonary administra-
tion in rats, while confocal imaging showed that smaller
particles were taken up more efﬁciently by alveolar macro-
phages.49 A study investigating the immunogenicity of differ-
ently sized PLGA particles (200, 500 and 1 mm) encapsulating
bovine serum albumin (BSA) showed that 1 mm-sized particles
were capable of inducing stronger IgG responses in vivo than
200 and 500 nm NPs following immunization via intranasal,
oral and s.c. routes in mice.42
Similar studies were conducted also with PLA MPs encapsu-
lating HBsAg, showing that MPs of 2-8 mm induced stronger
Table 1. Examples of analytical methods for characterization of antigen-containing
PLGA particles.
Particle characteristic Method
Particle size Dynamic light scattering
Nanoparticle tracking analysis
Light obscuration
Scanning electron microscopy
Transmission electron microscopy
Atomic force microscopy
Density Density gradient centrifugation
Helium compression pycnometry
Resonant mass measurement
Crystallinity X-ray diffraction
Differential scanning calorimetry
Surface chemistry X-ray photoelectron spectroscopy
Nuclear magnetic resonance
spectroscopy
Surface charge Electrophoresis
Laser Doppler velocimetry
Surface hydrophobicity Hydrophobic interaction
chromatography
Contact angle measurement
Two-phase partitioning
Antigen content, release and integrity Bicinchoninic acid assay
SDS-PAGE
High performance size-exclusion
chromatography
Reverse-phase high performance
liquid chromatography
Enzyme-linked immunosorbent assay
Fluorescence spectroscopy
UV/VIS spectroscopy
Fourier transform infrared
spectroscopy
Mass spectrometry
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anti-HBsAg antibody responses than NPs of 200-600 nm after
intramuscular (i.m.) immunization of rats.50 However, PLA
NPs were efﬁciently taken up by macrophages, whereas PLA
MPs primarily were found attached to the surface of the macro-
phages. Immunization with PLA MPs promoted IL-4 secretion,
upregulated MHC class II molecules and favored a Th2
response, whereas immunization with PLA NPs was associated
with higher levels of IFN-g production, upregulation of MHC
class I molecules along with antibody isotypes related to a Th1
response.50 Comparable results were obtained with i.m. vacci-
nation of rats with tetanus toxoid (TT) in PLA particles.48 So,
the choice of particle size may be dependent on the type of
immune response desired: NPs tend to favor a Th1 bias,
whereas MPs promote Th2 based responses.
After comparing the immunogenicity of TT loaded PLGA
NPs (500-600 nm) and MPs (4 mm), both types of particles
were mixed together into one formulation.51 After i.m. immu-
nization of rats, this mixture elicited higher antibody responses
compared to the NPs or MPs alone, which elicited similar
responses. A mixture of both size classes could also be consid-
ered to stimulate both Th1 and Th2 type responses.
Joshi et al. compared 17 mm, 7 mm, 1 mm, and 300 nm sized
PLGA particles co-encapsulating ovalbumin (OVA) and CpG,
by selectively recovering these particles with different centrifu-
gation cycles. They showed a size-dependent burst release over
48 h followed by a plateau, with total OVA and CpG release
ranging from 100% for 300 nm NPs to circa 10% for 17 mm
MPs.34 In a head-to-head comparison, they observed that the
efﬁciency of particle uptake and upregulation of MHC class I
and CD86 expression on murine bone marrow-derived den-
dritic cells (BMDC) correlated with smaller particle size.34 The
same trend was observed following intraperitoneal vaccination,
with the 300 nm NP generating the highest antigen-speciﬁc
cytotoxic T cell responses, and the highest IgG2a:IgG1 ratio of
OVA-speciﬁc antibodies, in proportion to DC uptake. These
results concur with our own observations, since we have
recently compared PLGA NP circa 300 nm with MP > 20 mm,
co-encapsulating OVA and poly(I:C), with similar composi-
tions and release properties, for their capacity to induce MHC
class I cross-presentation in vitro and improve immune
responses in vivo.47 NPs were efﬁciently internalized by DCs in
vitro, whereas MP were not. Subcutaneous vaccination of
C57BL/6 mice with NPs resulted in signiﬁcantly better priming
of Ag-speciﬁc CD8C T cells compared to MP. NP also induced
a balanced TH1/TH2-type antibody response, whereas MP
failed to increase antibody titers.47 These studies suggest that
Table 2. Comparative studies about the effect of PLGA particle size on the observed immune response.
Formulation Particle size Antigen/TLRL In vitro / in vivo Adminstration
route
Response References
PLGA MPs 5 mm, 12 mm HBsAg protein In vitro and in vivo Pulmonary 5 mm > 12 mm MPs uptaken
by rat alveolar
macrophages; Ab
responses: 5 mm > 12 mm
MPs
49
PLGA NPs & MPs 200 nm, 500 nm,
1 mm
BSA protein In vitro and in vivo s.c. Ab responses: 200 nm~500 nm
< 1 mm particles.
42
PLA NPs & MPs 200-600 nm, 2-
8 mm
HBsAg protein In vitro and in vivo i.m. NPs >> MPs uptaken by
macrophages; MPs " anti-
HBsAg Ab responses and "
IL-4 secretion related to a
Th2 response; NPs " IFN-g
production and " Ab
isotype related to a Th1
response.
50
PLA MPs < 2 mm, 2-8 mm,
10-70 mm, 50-
150 mm
TT In vivo i.m. Ab responses " by 2-8 mm MPs
> > 10-70 mm~50-150 mm.
48
PLGA NPs & MPs 500-600 nm,
3.5 mm
TT In vivo i.m. NPs and MPs mixed together "
Ab responses> NPs~MPs
alone
51
PLGA NPs & MPs 17 mm, 7 mm,
1 mm, 300 nm
OVA / Cpg ODN In vitro and in vivo i.p. Particle uptake and
upregulation of MHC class I
and CD86 expression and "
OVA-speciﬁc CD8C T cells
and " IgG2a:IgG1 following
the same size trend: :
17 mm << 7 mm < 1 mm
< 300 nm
34
PLGA NPs & MPs 300 nm,> 20 mm OVA / poly(I:C) In vitro and in vivo s.c. NPs >> MPs internalized by
DCs and " CD8C T cell
activation in vitro;
vaccination with NPs "
OVA-speciﬁc CD8C T cells &
Ab production, MPs did not
47
PLGA NPs & MPs 600 nm, 1 –
1.5 mm
OVA In vitro n/a MPs> NPs induced in vitro
MHC class I Ag cross-
presentation
52
Ab: antibody; Ag: antigen; <: less/lower than; >: more/higher than; <<: much less/lower than; >>: much more/higher than; ~: similar; ": increased/high: #:
decreased/low
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particulate vaccines should be formulated in the nano-size
range to achieve efﬁcient uptake, MHC class I cross-presenta-
tion and CTL responses.
Controlled antigen/adjuvant release
In addition to their ability to protect antigens, favor antigen
uptake by APCs and enhance the immune response, controlled
release systems can extend antigen release for prolonged peri-
ods of time.53,54 Antigen/adjuvant release from PLGA particles
is dependent on a variety of factors, such as size, polymer com-
position, porosity of the matrix, antigen loading or the way it is
associated with PLGA particles, i.e. encapsulated/entrapped or
adsorbed on the surface. In the ﬁrst case, antigen release
depends on the degradation, erosion or dissolution of the poly-
mer; whereas in the second case it is dependent on the interac-
tions between the polymer and the antigen.55 Entrapment of
the antigen within the particle matrix protects antigen from
external environment but may lead to incomplete release,
which could lead to a weak immune response; in contrast,
adsorption may lead to high burst release, prematurely releas-
ing the antigen from the particulate carrier before uptake by
DCs, which can lead to deﬁcient immune responses.36 Fre-
quently, a combination of adsorbed and encapsulated antigen
occurs, resulting in a characteristic triphasic release proﬁle with
an initial burst followed by a lag phase and a ﬁnal sustained
release phase of the encapsulated antigen dictated by polymer
erosion.55,56 Initial burst release of antigen can be generally
explained by 2 mechanisms: either by the release of antigens
that are adsorbed or located in the surface layer, or by antigen
escape through pores and cracks that may form during the fab-
rication process.57-59 Several factors affect burst release: higher
hydrophilicity, lower molecular weight and lower polymer con-
centration can lead to higher burst release.23,30,60 By adding
salts to the inner water phase (w1), the porosity of the resulting
particles can be controlled by increasing the osmotic gradient
and the ﬂux of water from w2 into the w1/polymer phase,
increasing antigen release rate.47 Suspensions of sugars61 or
salts in the oil phase are expected to act in a similar way, result-
ing in a major increase in water uptake, e.g., by incorporation
of suspended NaCl, which has been shown with PLGA ﬁlms.62
A larger inner surface, induced by a higher porosity of the par-
ticles, can potentially increase the uptake of the release medium
into the particles and accelerate the drug pore-diffusion and
release.63 After burst, the release of encapsulated material from
such systems is dependent on diffusivity through the polymer
barrier (a more hydrophobic polymer will create a higher bar-
rier), porosity, size of antigen molecule and distribution
throughout the matrix, leading to prolonged antigen release,
thereby enhancing the duration of antigen exposure to APCs
and thereby the potency of the resultant response.64
Antigen release kinetics regulate the antigen’s exposure
to the immune system. If most of the cargo is burst released
immediately after immunization and before uptake, antigen
will be delivered to APCs in soluble form, losing the beneﬁt
of particulate delivery.36 In contrast, if the release proﬁle is
too slow or incomplete, there will not be enough antigen
available for presentation by APCs. For instance, Hailemi-
chael et al. showed that Montanide-based persisting vaccine
depots can induce speciﬁc T cell sequestration, dysfunction
and deletion at vaccination sites, whereas short-lived formu-
lations may overcome these limitations and result in greater
therapeutic efﬁcacy of peptide-based cancer vaccines.65 Still,
sustained release of antigen/adjuvant seems crucial to prop-
erly activate DCs, whereas a low burst eliminates potential
antigen loss before uptake, increasing antigen presentation
and CD8C T cell activation.9,36 Kanchan et al. reported that
slow and continuous release of antigen/adjuvant may pro-
long MHC antigen presentation, which play a key role in T
cell stimulation and activation, and in eliciting memory
antibody responses.66 It has been reported that extended
antigen release may enhance not only the level, but also the
quality of immune responses.35 Johansen et al. demon-
strated that antigenic delivery increasing exponentially over
time induced more potent CD8C T cell responses and anti-
viral immunity than a single dose or multiple equivalent
doses (zero order).33 Shen et al. showed that OVA-loaded
PLGA MPs enhanced exogenous antigen MHC class I
cross-presentation at 1000-fold lower concentration than
soluble antigen, and served as an intracellular antigen reser-
voir, leading to sustained MHC class I presentation of OVA
for 72 h.16 Likewise, Waeckerle-Men et al. showed that
MHC classes I and II-restricted presentation of proteins
and peptides encapsulated in PLGA MPs (0.5 – 5 mm) was
markedly prolonged and presented 50-fold more efﬁciently
on class I molecules than soluble antigens.67 A difference in
performance between PLGA NPs connected to the kinetics
of antigen delivery was shown by Demento et al., with
“slow” releasing NPs eliciting prolonged antibody titers
comparing to “fast” releasing ones.9 Moreover, “slow”
release favored long-term effector-memory cellular
responses. Finally, Zhang et al. formulated OVA-loaded
PLGA NPs by encapsulating antigen within NPs or by sim-
ply mixing soluble antigen with the NPs, observing that the
combined formulations induced more powerful antigen-spe-
ciﬁc immune responses than each single-component formu-
lation. The enhanced immune responses elicited by the
combined vaccine formulation may be ascribed to the com-
bination of a depot effect at the injecton site, adequate ini-
tial antigen exposure and long-term antigen persistence
leading to prolonged antigen presentation.68
Surface characteristics
Surface characteristics such as shape, hydrophobicity, and zeta
potential are reported to inﬂuence phagocytic uptake by APCs.
Because cells are negatively charged, cationic particles induce
phagocytic uptake more efﬁciently than anionic particles,
owing to electrostatic attraction to the negatively charged APC
membranes.69,70 Strategies aimed at improving the efﬁcacy of
PLGA particles as antigen delivery vehicles involve coating
them with ionic surfactants or polymers such as poly(ethylene
glycol) (PEG), sodium dodecyl sulfate (SDS), aminodextran,
chitosan, poly(ethylene imine) (PEI), poly(L-lysine), protamine
or cetyltrimethylammonium bromide (CTAB).55,71,72 Coating
can be achieved either by incorporating these agents in the par-
ticle matrix (together with the polymer or in the external aque-
ous phase during the emulsiﬁcation process), or by adsorption
to the surface of pre-formed particles by resuspending them in
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Table 3. Examples of reports of PLGA formulations using Toll-like receptor ligands and their immunological effects.
Receptor Ligand Formulation Antigen In vitro / in vivo Adminstration
route
Response References
TLR 1/2 Pam3CSK4 PLGA NPs (~350 nm) OVA24 peptide In vitro and in vivo s.c. TLR 2 stimulation " MHC class I
presentation of OVA24-NPs by DCs
in vitro and " prolonged Ag
presentation and CD8C T cell
activation in vivo after adoptive
transfer of NP-loaded DCs
96
Pam3CSK4 PLGA NPs (~500)
and MPs (~2 mm;
mm)
CS252-260 coupled
to Pam3CSK4
(Pam-CS252-260)
In vivo i.p Pam-CS252-260 particles " cytolytic
activity > CS252-260-MPs or sPam-
CS252-260; 500 nm NPs > 2 mm~mm
MPs inducing CTL responses
95
TLR 3 Poly(I:C) (DEAE)–dextran-
PLGA MPs
(~3 mm)
FITC-BSA In vitro n/a poly(I:C) coated-MPs " expression of
CD80, CD86, and CD83 at the DC
surface~cytokine cocktail or "
concentrations of sPoly(I:C).
84
TLR 4 MPLA PLGA MPs (1 –
10 mm)
OVA323-39 peptide;
MUC1 mucin
peptide
In vivo s.c. Ag/MPLA-MPs " T cell proliferative
response and production of IFN-
g by T cells, eliciting a speciﬁc Th1
immune response> Ag-MPs or Ag
mixed with alum
87,88
MPLA PLGA NPs (350 –
450 nm)
OVA protein In vitro and in vivo i.p. or s.c. OVA/MPLA-NPs " CD8C T cell
proliferative responses & IFN-g in
vitro and>13-folds increase in
clonal expanded CD4C T cells in
vivo > OVA-NPs
89
MPLA PLGA NPs (~300 nm) HBcAg protein In vivo s.c. HBcAg/MPLA-NPs " Th1 cellular
response with predominant IFN-g
proﬁle > sHBcAg, sHBcAg/sMPLA,
or HBcAg-NPs
91
MPLA PLGA NPs (~500 nm) HBcAg129–140 In vivo s.c. HBcAg129–140/MPLA-NPs " Th1-type
response> control formulation of
HBcAg129–140in CFA
92
MPLA PLGA NPs (350 –
450 nm)
OVA; MUC1
lipopeptide
(BLP25)
In vitro and in vivo n/a OVA/MPLA-NPs " in vitro and in vivo
antigen-speciﬁc primary Th1
immune responses> OVA-NPs or
sOVA/sMPLA after adoptive transfer
of antigen-pulsed DCs; MUC1/
MPLA-NPs delivery to DCs " MUC1
reactive T cells in vitro > MUC1-
NPs, MPLA-NPs, sMUC1, or sMUC1
with MPLA-NPs
10
7-acyl lipid A PLGA NPs (350 –
410 nm)
TRP2180-188peptide In vivo s.c. TRP2180-188/7-acyl lipid A-NPs " CD8C T
cell-mediated anti-tumor immunity
and therapeutic anti-tumor effect
and levels of IFN-g and pro-
inﬂammatory Th1-related cytokines
> TRP2180-188-NPs
90
MPLA PLGA NPs (~80 nm) TRP2180-188peptide In vitro and in vivo i.d. NP " uptake in vitro and in vivo;
TRP2180-188/MPLA-NPs # growth of
s.c. inoculated B16 melanoma cells
in a prophylactic setting> TRP2180-
188-NPs, sTRP2180-188/sMPLA
93
MPLA or RC529 PLGA MPs (3 –
5 mm)
gp120 protein;
MenB
In vivo i.p. Ag adsorbed on TLRL-MPs " IgG serum
titers> Ag adsorbed-MPs with
sTLRL.
94
TLR 9 CpG ODN PLGA NPs (~300 nm) Tetanus toxoid (TT) In vitro and in vivo s.c. TT/CpG-NPs " antigen-speciﬁc T cell
proliferation ex vivo & IFN-g
secretion and 16-fold IgG titers>
sTT/sCPG; co-encapsulation " Th1
and Th2 immune responses toward
Th1 type bias.
80
CpG ODN PLGA MPs (mm) OVA protein; CpG-
OVA conjugate
In vitro and in vivo s.c. OVA/CpG-MPs were uptaken by DCs in
vitro; OVA/CpG-MPs " Ag-speciﬁc
CD4C and CD8C T cells~CPG-OVA
conjugates in vivo. In a tumor
challenge, MPs caused complete
tumor regression in 4 out of 5 mice.
82
CpG ODN PLGA MPs (mm) PLA2 protein In vivo s.c. PLA2/CPG-MPs " PLA2-speciﬁc Ab
responses and " Th1-associated
isotype IgG2a. The effect of CpG "
when protamine was co-
76
(Continued)
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a solution containing the coating and incubating for a deter-
mined amount of time. Besides changing surface charge, some
of these molecules have bioadhesive properties, such as chito-
san,1 which has been employed to develop formulations for
mucosal delivery. Polycations can also aid in phagosomal/
endosomal escape after being internalized by APCs,1 potentially
improving MHC class I presentation and CTL responses.
Wishke et al. studied the impact of the surface properties of
MPs (5 – 10 mm) on phagocytosis, using BSA bearing ﬂuores-
cein isothiocyanate groups (FITC-BSA) as model antigen.72
Modiﬁcation with chitosan and DEAE-dextran resulted in sta-
ble MPs and increased cellular uptake by DCs. Positively
charged PLGA MPs (1 – 5 mm) containing hepatitis B surface
antigen (HBsAg) were prepared with cationic agents stearyl-
amine and PEI in the external aqueous phase.69 Compared to
unmodiﬁed formulations, positive surface charge enhanced
both the systemic and mucosal immune response upon immu-
nization of rats via the intranasal route. PLGA MPs containing
recombinant HBsAg and coated with chitosan were developed
for nasal immunization.73 The modiﬁed PLGA microspheres
showed the lowest nasal clearance rate and a 30-fold increase of
serum IgG levels. OVA-loaded PLGA NPs coated with N-tri-
methyl chitosan (TMC) were more efﬁciently taken up by DCs
and showed a longer nasal residence time than uncoated
particles.74
Protamine, a cationic polypeptide, has been used as a sur-
face-coating material because of its ability of increasing cell
penetration.75 Protamine coating of PLGA MPs (~7 mm) encap-
sulating the puriﬁed phospholipase A2 (PLA2) from bee venom
or OVA injected s.c. in mice led to increased antibody and T-
cell responses as compared to uncoated particles (~3 mm), most
likely mediated by an increased uptake. In another study from
the same group, combination of adsorbed protamine and CpG
(~8 mm) resulted in strong PLA2-speciﬁc antibody responses
and the induction of the Th1-associated isotype IgG2a.76 How-
ever, when the MHC class I-restricted OVA peptide SIINFEKL
was encapsulated into bare PLGA MPs, protamine- or chito-
san-coated MPs with CpG either covalently coupled or physi-
cally adsorbed on their surface,77 only the uncoated MPs with
adsorbed CpG mediated a prominent CTL response in mice
after s.c. immunization, with failure of the other formulations
being ascribed to the low release of antigen and CpG.
In conclusion, modifying the surface charge may help
increase particle uptake efﬁciency and result in a stronger
immune response, especially when considering mucosal deliv-
ery. Furthermore, modiﬁcation of the particle surface using
either polycations or polyanions has been used to create cat-
ionic or anionic particles to which charged antigens/adjuvants
can be adsorbed, which may be beneﬁcial to improve antigen
stability.
Table 3. (Continued )
Receptor Ligand Formulation Antigen In vitro / in vivo Adminstration
route
Response References
encapsulated for complexation of
CpG.
CpG ODN bare, chitosan-
coated, and
protamine-
coated PLGA
MPs (mm)
SIINFEKL peptide In vivo s.c. Only uncoated SIINFEKL-MPs with
adsorbed CpG " IFN-g secreting
and SIINFEKL-speciﬁc CD8C T cells.
77
CpG ODN PLGA MPs (~1 –
1.5 mm) coated
with CTAB or
DSS
p55 gag or gp120
env proteins
In vitro and in vivo i.m. CpG adsorbed to PLGA-CTAB MPs co-
administered with gp120 env or
p55 gag proteins adsorbed to
PLGA-DSS MPs " Ag-speciﬁc serum
IgG titers, as well as CTL responses
against p55 gag > sCp/sAg,
102
CpG ODN-chitosan
complexes
PLGA 502 and 752
MPs (~1 – 2 mm)
OVA protein In vivo i.d. OVA/CpG-MPs " Ab response and
isotype shifting to Th1 > OVA- MPs.
81
TLR 9 &
TLR 3
CpG ODN or Poly(I:
C)
PLGA MPs (mm) OVA protein In vivo s.c. CpG/OVA- or poly(I:C)/OVA-MPs " (i)
SIINFEKL/H-2Kb tetramer positive
CTLs, (ii) IFN-g production, (iii) in
vivo cytotoxicity and (iv) protection
from vaccinia virus > to OVA-MPs
with sTLRL or OVA-MPs with TLRL-
MPs.
79
CpG ODN & Poly(I:
C)
PLGA MPs (~0.5 -
5 mm)
OVA protein In vivo s.c. OVA/CpG-MPs with MP-poly(I:C)  IFA
in eradication of preexisting tumors
and suppression of lung metastases
85
CpG ODN or/and
Poly(I:C)
PLGA NPs (~1 mm) OVA protein In vitro poly(I:C)/OVA- or CpG/OVA-NPs "
prolonged MHC class I- & II-
restricted presentation and " OVA-
speciﬁc CD8C and CD4C T cells;
combination of both TLRLs
synergistically " MHC class I-
restricted, but not class II, Ag
presentation.
86
Ab: antibody; Ag: antigen; <: less/lower than;>: more/higher than;<<: much less/lower than;>>: much more/higher than; : equal or higher than;~: similar; ":
increased/high: #: decreased/low; CFA: complete Freund’s adjuvant; sX: soluble X
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Targeted delivery to DCs
TLRL co-delivery in PLGA systems. One of the greatest bene-
ﬁts of particulate antigen delivery systems is their ability to co-
deliver antigens and immunostimulatory molecules simulta-
neously to the same APCs.78 The concomitant delivery of
TLRLs and antigens in PLGA particles has been proven suc-
cessful to enhance antigen-speciﬁc CTL responses.77,79 The
appropriate selection of the TLRL for co-delivery will deter-
mine the bias toward Th1 or Th2 responses.78 Furthermore, as
most pathogens simultaneously present multiple TLR agonists
to APCs, the combination of multiple TLRLs may result in a
synergistic effect and a promising strategy to induce strong pro-
tective immune responses.8 Over the last decades, some of these
ligands have been used in several vaccine formulations to target
and activate TLRs.
Most commonly delivered TLRLs in PLGA particulate sys-
tems include CpG, a ligand to TLR9 which is known to induce
a MHC class I driven antigen presentation;80-83 poly(I:C), a
TLR3L analog to viral double-stranded RNA, which is also
known to enhance cross-priming of CD8C cytotoxic T lympho-
cytes;79,84-86 monophosphoryl lipid A (MPLA), a detoxiﬁed
form of lipid A derived from LPS which is a potent TLR4 ago-
nist;10,87-94 the TLR1/2 agonist Pam3CSK4, a synthetic tripal-
mitoylated lipopeptide that mimics the acylated N-terminus of
bacterial lipoproteins;14,95,96 and small synthetic molecules like
single-stranded RNA analogs and imidazoquinolines, such as
resiquimod (R848),11 recognized by TLR7 and TLR8. Co-deliv-
ery of TLRLs and antigen with PLGA particles consistently
increased the effectiveness of the adjuvants, with the impor-
tance of co-encapsulation being shown in several studies.10,79,81
A combination of TLR agonists can act synergistically to
increase MHC class I-restricted presentation of exogenous anti-
gen, resulting in more potent cellular responses.11,14,86 A sum-
mary of PLGA vaccine formulations containing TLRLs can be
found in Table 3.
Conjugation of antigens to adjuvants to increase their
immunogenicity has been successfully achieved.82,83,97-100 This
Table 4. Examples of studies of PLGA particles targeted to DCs.
Receptor Formulation Antigen / adjuvant In vitro /in vivo Administration
route
Response compared to
untargeted particles
References
Integrin, lectin and mannose
receptors
PLGA MPs (~2.5 mm) c.c. to RGD
peptide; WGA; mannose-
PEG3-NH2
– In vitro n/a " uptake of targeted MPs 108
Integrin receptor PLGA NPs (~200 nm) c.c. to RGD
peptide
OVA In vitro and and in
vivo
Oral "uptake by M cells and " IgG
responses in vivo
107
PLGA MPs (~1 mm) containing
alginate or c.c. RGD-
alginate
SPf66; S3 In vivo i.d. " Ab and cellular responses
and more balanced Th1/Th2
responses; " IFN-g
secretion and splenocyte
proliferation
109
Mannose receptor Mannan c.c. to PLGA NPs
(~400 nm)
OVA In vitro and and in
vivo
s.c. " antigen-speciﬁc CD4C and
CD8C T cell responses in
vitro and and vivo
113
Mannan-coated on or c.c. to
PLGA NPs (~400-500 nm)
– In vitro n/a " DC uptake and cell surface
markers (CD40, CD86) and
secretion of inﬂammatory
cytokines (IL-12, IL-6 and
TNF-a)
111,114
DC-SIGN PLGA MPs (2 mm) and NPs
(200 nm) c.c. to humanized
hD1 anti-DC-SIGN antibody
BSA; TT In vitro n/a MPs were taken up
nonspeciﬁcally; NPs
effectively targeted DCs: "
uptake & Ag-speciﬁc T cell
responses at 10–100 fold
lower concentrations
12
DEC-205 PLGA NPs (~200 nm) c.c. to bfFp
containing anti-DEC-205
antibody fragment
OVA In vitro and and in
vivo
s.c. 2-fold " receptor-mediated
uptake of bfFp
functionalized NPs in vitro;
" OVA-speciﬁc IgG
responses in vivo
117
DEC-205 PLGA NPs (~200-250) c.c. to anti-
DEC-205 mAb
OVA / KRN In vitro and and in
vivo
Footpads " antigen-speciﬁc humoral &
CTL responses and
promoted potent antitumor
responses
119
DEC-205; CD40; CD11 PLGA NPs (200 nm) c.c. either
with anti-DEC-205, -aCD40
or -CD11 mAbs
OVA / poly(I:C) &
R848
In vitro and and in
vivo
s.c. " uptake of targeted NPs & IL-
12 production and
expression of IFN-g in vitro;
" OVA-speciﬁc CD8C T cell
responses in vivo
11
CD40 PLGA NPs (200 nm) c.c. with
anti-aCD40 mAb
OVA; HPV-E7 / poly
(I:C) &
Pam3CSK4
In vitro and and in
vivo
" selective delivery to DCs and
" CD8C T cell priming in
vitro; " tumor control and
prolonged survival of
tumor-bearing mice in vivo
14
Ab: antibody; Ag: antigen; <: less/lower than;>: more/higher than;<<: much less/lower than;>>: much more/higher than; : equal or higher than;~: similar; ":
increased/high: #: decreased/low; CFA: complete Freund’s adjuvant; sX: soluble X; c.c.: chemically conjugated; bfFp: bifunctional fusion protein of strepatividin
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approach, however, requires processes that have to be devel-
oped and optimized for each individual antigen-adjuvant com-
bination, whereas particulate formulations offer a more generic
approach.
The best way to deliver adjuvants with PLGA particles, by
either entrapment or adsorption, is yet to be resolved. The bet-
ter choice likely depends on the cellular location of their target
receptors: if they act on the cell surface, it might be desirable to
have the adjuvant readily available on uptake; but if they need
to be internalized to interact with endosomal receptors, encap-
sulation within the particle might be preferable.101
Targeted delivery to other DC receptors. Aside from TLR
ligands, there are other targeting ligands that have been used
with PLGA particles to increase the immunogenicity of subunit
vaccines (see Table 4). This can be achieved by modifying the
particle surface with ligands that can target speciﬁc surface
receptors of APCs, by either physical association or conjugation
reactions.1,5 Physical association is driven by electrostatic and
hydrophobic interactions, whereas preformed PLGA nanopar-
ticles with carboxyl end groups can be chemically conjugated
with molecules with terminal amine groups via amide coupling
reactions using carbodiimide reagents.103 To that end, the sur-
face of PLGA is ﬁrst derivatized by PEG-NH2 with functional
end groups that can react with different ligands, such as biotin-
PEG-NH2.
103 As avidin and its homologues show very high
afﬁnity to biotin, biotinylated PEG-PLGA particles allow non-
covalent binding with avidin-ligand conjugates or vice versa,
allowing targeting ligands such as antibodies to be attached to
PLGA particles.103 Interaction between PLGA particles func-
tionalized with speciﬁc ligands and/or antibodies against DC
receptors may improve targeting to DCs, increase particle
uptake by DCs through receptor-mediated endocytosis and
modulate DC maturation, and thereby enhance the effective-
ness of the vaccine formulation.104
M-cell targeting can be considered if the vaccine is adminis-
tered at a mucosal tissue.105,106 Integrins are heterodimeric
transmembrane subunits that have speciﬁc afﬁnities toward
peptides with an arginine-glycine-aspartate (RGD) sequence103
and are highly expressed on M-cells. Grafting of integrin-bind-
ing RGD peptides can be used to promote the uptake of NPs
via interaction with b1 integrins on M-cells.107-109
C-type lectin receptors (CLRs) are endocytic receptors that
recognize exogenous and endogenous carbohydrates which are
present on the surface of DCs and macrophages.103 Antigens
associated with speciﬁc sugar residues can target to these recep-
tors on DCs, including the mannose receptor, DEC-205 (also
known as CD205), and DC-speciﬁc intracellular adhesion mol-
ecule-3 (ICAM3)-grabbing non-integrin (DC-SIGN).110 Two
main strategies can be used to target CLRs, either by grafting
particles with speciﬁc sugar residues which are natural ligands
for these endocytic receptors (e.g., sugars with terminal man-
nose, fucose or N-acetylglucosamine) or by coupling mAbs
against them.111,112 Many CLRs expressed by DCs are directly
implicated in immunoregulatory processes, such as antigen
uptake, intracellular trafﬁcking and antigen presentation.110
PLGA particles decorated with mannan, a natural polymannose
isolated from the cell wall of Saccharomyces cerevisiae, have
been designed for targeted DC delivery via mannose
receptors.111,113-116 DEC-205 has successfully been used to tar-
get DCs in vivo.112,117,118 A study by Cruz et al. using antigen-
loaded NPs conjugated to anti-DC-SIGN targeting antibody
improved activation of antigen-speciﬁc T-cell responses at 10–
100 fold lower concentrations of antigen compared to the non-
targeted NPs.12 Similar studies targeting DEC-205, CD40 or
CD11 increased uptake by DCs and CD8C T cell activation,
showing that targeting to speciﬁc DC receptors is a viable
approach to increase the efﬁcacy of particulate vaccines.11,14
Conclusions
Vaccination with subunit antigens is not always successful due
to their limited bioavailability and poor immunogenicity.
Moreover, soluble antigens are often inefﬁciently cross-pre-
sented. Delivery systems can be used in order to overcome
these problems, by protecting antigens from degradation and
increase their biodistribution and ability to reach and be
uptaken by APCs. The main advantages and disadvantages of
PLGA-based particulate vaccine delivery systems are summa-
rized in Table 5.
Depending on their physicochemical characteristics, delivery
systems can modulate the immune response, mainly due to
direct inﬂuence in the following mechanisms: facilitated uptake
by APCs, regulation of the internalization pathways and ability
to endosomal escape, and interaction with speciﬁc receptors
that mediate the immune response toward humoral or cellular
bias. The main immunogenic properties of viruses that elicit
potent immune responses may serve as a base for rational vac-
cine design.120
Table 5. Summary of the main advantages and disadvantages of PLGA-based
particulate vaccine delivery systems.
Advantages Disadvantages
 PLGA polymers are biodegradable,
widely available and approved by
regulatory agencies such as FDA
 PLGA particles for delivery of
several different agents are on the
market
 PLGA particles can be administered
via various routes
 PLGA particles may decrease
toxicity of vaccine components
 Particle size, surface and/or release
characteristics can be tailored
 PLGA particles allow controlled Ag
release
 PLGA particles protect Ag from
degradation and elimination
 PLGA particles enhance Ag uptake
by APCs by mimicking size and
shape of pathogens
 PLGA particles enhance and
prolong Ag cross-presentation
efﬁciency
 PLGA particles allow concomitant
delivery of multiple vaccine
components
 Large surface area and surface
functional groups allow
conjugating of targeting moieties
 PLGA particles may lead to Ag dose
sparing
 Negative charge of PLGA particles
is disadvantageous for particle
uptake
 PLGA particle preparation process
must be tailored to the properties
of the Ag
 PLGA particles cannot be sterile
ﬁltered
 Ag degradation may occur during
preparation, storage and release
 Ag release is often incomplete
 Particle aggregation may occur
 Particle size may limit crossing of
biological barriers
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Most studies are clear: size plays a crucial role in vaccine efﬁ-
cacy. Smaller particles tend to be more immunogenic due to
their easier uptake by DCs and more efﬁcient transport in the
lymphatic system, where they can reach immature DC subsets;
still, microparticles can form stable antigen depots and are
more suitable for inhalable pulmonary vaccination.1 Recent
studies have suggested that smaller particles mostly induce cel-
lular immunity while larger particles tend to induce humoral
responses.1,35 Other important factors include release kinetics;
surface characteristics; concomitant delivery of antigen and
immunostimulants, allowing DCs to associate danger signals
with the antigen, while co-encapsulation of multiple TLRLs
may result in a synergistic effect; coating or coupling of DC-
speciﬁc targeting moieties, increasing DC uptake and enhanc-
ing antigen presentation to T cells. Future developments in vac-
cine delivery will likely involve the combination of
immunostimulants with delivery vehicles modiﬁed with DC-
speciﬁc targeting ligands or antibodies.
In summary, vaccines that mimic the size, charge, release
kinetics and PAMPs of pathogens may be the future of pep-
tide-based immunotherapy of cancer and/or other diseases that
cannot be treated by conventional vaccines.
Abbreviations
Ab Antibody
Ag Antigen
APC Antigen-presenting cell
BMDC Bone marrow-derived dendritic cells
BSA Bovine serum albumin
CD4C T cell T helper cell
CD8C T cell Cytotoxic T lymphocyte
CFA Complete Freund’s adjuvant
CLR C-type lectin receptor
CpG ODN Unmethylated cytosine-phosphodiester-guanine
oligodeoxynucleotide motif
CTAB Cetyltrimethylammonium
CTL Cytotoxic T lymphocyte
CTLA-4 Cytotoxic T lymphocyte-associated antigen 4
DC Dendritic cell
DEAE Diethylaminoethyl
DNA DNA
DOTAP Dioleoyl-trimethylammonium-propane
DSS Dioctylsulfosuccinate
FDA Food and Drug Administration
FITC Fluorescein isothiocyanate
gp Glycoprotein
HBcAg Hepatitis B core antigen
HBsAg Hepatitis B surface antigen
HPLC High-performance liquid chromatography
HPV Human papillomavirus
i.d. Intradermal
i.m. Intramuscular
i.n. Intranasal
i.p. Intraperitoneal
IFA Incomplete Freund’s adjuvant
IgG Immunoglobulin G
IgG1 Immunoglobulin G subtype 1
IgG2a/b Immunoglobulin G subtype 2a/b
IL Interleukin
INF-g Interferon gamma
ISCOM Immune stimulatory complex
LPS Lipopolysaccharide
mAb Monoclonal antibody
M-cell Microfold cell
Men B Neisseria meningitidis serotype B
MHC I/II Major histocompatibility complex class I/II
MP Microparticle
MPLA Monophosphoryl lipid A
NOD Nucleotide-binding oligomerization domain
receptor
NP Nanoparticle
o/w Oil-in-water (emulsion)
OVA Ovalbumin
OVA17 17-residue synthetic long peptide of ovalbumin
(ISQAVHAAHAEINEAGR)
OVA24 24-residue synthetic long peptide of ovalbumin
(DEVSGLEQLESIINFEKLAAAAAK)
Pam3CSK4 Synthetic triacylated lipopeptide
PAMP Pathogen associated molecular pattern
PEG Poly(ethylene glycol)
PEI Poly(ethylene imine)
PLA Poly(lactic acid)
PLA2 Phospholipase A2
PLGA Poly(lactic-co-glycolic acid)
Poly(I:C) Polyinosinic:polycytidylic acid
PRR Pattern recognition receptor
RGD Arginine-glycine-aspartate
RNA Ribonucleic acid
RP-HPLC Reversed-phase high-pressure liquid
chromatography
s.c Subcutaneous
SDS Sodium dodecyl sulfate
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel
electrophoresis
SEM Scanning electron microscopy
Th T helper
Th1 Type 1 helper T
Th2 Type 2 helper T
TLR Toll-like receptor
TLRL Toll-like receptor ligand
TMC N-trimethyl chitosan
TNF Tumor necrosis factor
TRP1/2 Tyrosinase-related protein 1/2
TT Tetanus toxoid
w/o/w Water-in-oil-in-water (emulsion)
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